Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2026)

Regeneron Pharmaceuticals' Intangibles history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Intangibles rose 10.27% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 10.27% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 9.47% from the prior year.
• Intangibles grew to $1.3 billion in Q1 2026 per REGN's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Intangibles topped out at $1.4 billion in Q3 2025 and bottomed at $155.0 million in Q2 2025.
• The 5-year median for Intangibles is $1.1 billion (2024), against an average of $1.0 billion.
• Across the five-year window, Intangibles soared 13564.18% in 2022 and slumped 85.94% in 2025, its largest moves.
• Year by year, Intangibles stood at $915.5 million in 2022, then rose by 13.45% to $1.0 billion in 2023, then increased by 10.59% to $1.1 billion in 2024, then climbed by 9.47% to $1.3 billion in 2025, then rose by 2.35% to $1.3 billion in 2026.
• Per Business Quant, the three latest REGN Intangibles figures stand at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025).